曼吉费林通过AKR1B1调节脂质代谢,以应对先进的糖化终产品
Saphy Sharda1,2, Abhishek Aher1, Debasish Kumar Ghosh3
1Laboratory of Immunology, Centre for DNA Fingerprinting and Diagnostics, Hyderabad, India.
糖尿病外围神经病变涉及脂质代谢的变化. AKR1B1基因驱动脂质滴形成,但曼吉费林抑制了这一点,为糖尿病神经病变提供了潜在的治疗方法.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 神经科学是一个神经科学.
背景情况:
- 糖尿病外围神经病变 (DPN) 的特点是脂肪代谢受损.
- 在高血糖条件下,AKR1B1基因在DPN上调.
- 假设AKR1B1在神经细胞中促进脂质液滴的形成.
研究的目的:
- 在DPN的背景下,研究AKR1B1在脂质代谢中的作用.
- 通过先进的糖化终产品 (AGEs) 探索AKR1B1的调节.
- 为了识别和验证治疗干预的潜在AKR1B1抑制剂.
主要方法:
- 对DPN试验组的转录组分析.
- 使用了人类神经母细胞瘤 (IMR-32) 细胞模型.
- 对AKR1B1抑制进行选的异环化合物,随后进行分子对接,动力学模拟和生物化学测试.
主要成果:
- AKR1B1被确定为DPN中的关键脂质代谢调节剂.
- AGE-HSA治疗通过OCT1酸化增加了AKR1B1的表达和活性.
- 曼吉费林被确定为一种强大的AKR1B1抑制剂,减少脂质滴积累,并抵消AGE诱导的脂质失调.
结论:
- AKR1B1是DPN中脂质代谢的关键调节者.
- 曼吉费林通过抑制AKR1B1.1.表现出治疗潜力.
- 曼吉费林可以恢复糖尿病神经病变中的脂质平衡.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
04:46Differentiation and Imaging of Brown Adipocytes from the Stromal Vascular Fraction of Interscapular Adipose Tissue from Newborn Mice
Published on: February 3, 2023
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
GPCRs Regulate Adenylyl Cylase Activity
Insulin: The Receptor and Signaling Pathways
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
